Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia

Éva Karászi, Katalin Jakab, L. Homolya, G. Szakács, Zsolt Holló, Béla Telek, Attila Kiss, László Rejtô, Sarolta Nahajevszky, B. Sarkadi, J. Kappelmayer

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

In this study, we evaluated the suitability of the calcein assay as a routine clinical laboratory method for the identification of multidrug-resistant phenotype in acute leukaemia. This study presents the results of the calcein tests obtained in two large haematological centres in Hungary. Assays were performed with blast cells of 93 de novo acute leukaemia patients, including 65 patients with acute myeloid leukaemia (AML). Results were expressed as multidrug resistance activity factor (MAF) values. AML patients were divided into responders and non-responders and MAF values were calculated for each group. In both centres, responder patients displayed significantly lower MAF values than non-responders (P = 0.0045 and P = 0.0454). Cut-off values were established between the MAFR + SEM and MAFNR - SEM values. On the basis of these cut-off levels, multidrug resistance (MDR) negativity showed a 72% predictive value for the response to chemotherapy, whereas MDR positivity was found to have an average predictive value of 69% for therapy failure. MDR activity was a prognostic factor for survival rate and the test was suitable for detecting patients at relapse. The calcein assay can be used as a quantitative, standardized, inexpensive screening test in a routine clinical laboratory setting. The assay detects both P-glycoprotein and multidrug resistance-associated protein activities, and identifies AML patients with unfavourable therapy responses.

Original languageEnglish
Pages (from-to)308-314
Number of pages7
JournalBritish Journal of Haematology
Volume112
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Multiple Drug Resistance
Acute Myeloid Leukemia
Survival Rate
R Factors
Leukemia
Therapeutics
Multidrug Resistance-Associated Proteins
Hungary
P-Glycoprotein
fluorexon
Phenotype
Recurrence
Drug Therapy

Keywords

  • Acute myeloid leukaemia
  • Calcein-AM
  • P-glycoprotein
  • Verapamil

ASJC Scopus subject areas

  • Hematology

Cite this

Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. / Karászi, Éva; Jakab, Katalin; Homolya, L.; Szakács, G.; Holló, Zsolt; Telek, Béla; Kiss, Attila; Rejtô, László; Nahajevszky, Sarolta; Sarkadi, B.; Kappelmayer, J.

In: British Journal of Haematology, Vol. 112, No. 2, 2001, p. 308-314.

Research output: Contribution to journalArticle

Karászi, Éva ; Jakab, Katalin ; Homolya, L. ; Szakács, G. ; Holló, Zsolt ; Telek, Béla ; Kiss, Attila ; Rejtô, László ; Nahajevszky, Sarolta ; Sarkadi, B. ; Kappelmayer, J. / Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. In: British Journal of Haematology. 2001 ; Vol. 112, No. 2. pp. 308-314.
@article{1e8d6efb242f4617a27e57142a439744,
title = "Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia",
abstract = "In this study, we evaluated the suitability of the calcein assay as a routine clinical laboratory method for the identification of multidrug-resistant phenotype in acute leukaemia. This study presents the results of the calcein tests obtained in two large haematological centres in Hungary. Assays were performed with blast cells of 93 de novo acute leukaemia patients, including 65 patients with acute myeloid leukaemia (AML). Results were expressed as multidrug resistance activity factor (MAF) values. AML patients were divided into responders and non-responders and MAF values were calculated for each group. In both centres, responder patients displayed significantly lower MAF values than non-responders (P = 0.0045 and P = 0.0454). Cut-off values were established between the MAFR + SEM and MAFNR - SEM values. On the basis of these cut-off levels, multidrug resistance (MDR) negativity showed a 72{\%} predictive value for the response to chemotherapy, whereas MDR positivity was found to have an average predictive value of 69{\%} for therapy failure. MDR activity was a prognostic factor for survival rate and the test was suitable for detecting patients at relapse. The calcein assay can be used as a quantitative, standardized, inexpensive screening test in a routine clinical laboratory setting. The assay detects both P-glycoprotein and multidrug resistance-associated protein activities, and identifies AML patients with unfavourable therapy responses.",
keywords = "Acute myeloid leukaemia, Calcein-AM, P-glycoprotein, Verapamil",
author = "{\'E}va Kar{\'a}szi and Katalin Jakab and L. Homolya and G. Szak{\'a}cs and Zsolt Holl{\'o} and B{\'e}la Telek and Attila Kiss and L{\'a}szl{\'o} Rejt{\^o} and Sarolta Nahajevszky and B. Sarkadi and J. Kappelmayer",
year = "2001",
doi = "10.1046/j.1365-2141.2001.02554.x",
language = "English",
volume = "112",
pages = "308--314",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia

AU - Karászi, Éva

AU - Jakab, Katalin

AU - Homolya, L.

AU - Szakács, G.

AU - Holló, Zsolt

AU - Telek, Béla

AU - Kiss, Attila

AU - Rejtô, László

AU - Nahajevszky, Sarolta

AU - Sarkadi, B.

AU - Kappelmayer, J.

PY - 2001

Y1 - 2001

N2 - In this study, we evaluated the suitability of the calcein assay as a routine clinical laboratory method for the identification of multidrug-resistant phenotype in acute leukaemia. This study presents the results of the calcein tests obtained in two large haematological centres in Hungary. Assays were performed with blast cells of 93 de novo acute leukaemia patients, including 65 patients with acute myeloid leukaemia (AML). Results were expressed as multidrug resistance activity factor (MAF) values. AML patients were divided into responders and non-responders and MAF values were calculated for each group. In both centres, responder patients displayed significantly lower MAF values than non-responders (P = 0.0045 and P = 0.0454). Cut-off values were established between the MAFR + SEM and MAFNR - SEM values. On the basis of these cut-off levels, multidrug resistance (MDR) negativity showed a 72% predictive value for the response to chemotherapy, whereas MDR positivity was found to have an average predictive value of 69% for therapy failure. MDR activity was a prognostic factor for survival rate and the test was suitable for detecting patients at relapse. The calcein assay can be used as a quantitative, standardized, inexpensive screening test in a routine clinical laboratory setting. The assay detects both P-glycoprotein and multidrug resistance-associated protein activities, and identifies AML patients with unfavourable therapy responses.

AB - In this study, we evaluated the suitability of the calcein assay as a routine clinical laboratory method for the identification of multidrug-resistant phenotype in acute leukaemia. This study presents the results of the calcein tests obtained in two large haematological centres in Hungary. Assays were performed with blast cells of 93 de novo acute leukaemia patients, including 65 patients with acute myeloid leukaemia (AML). Results were expressed as multidrug resistance activity factor (MAF) values. AML patients were divided into responders and non-responders and MAF values were calculated for each group. In both centres, responder patients displayed significantly lower MAF values than non-responders (P = 0.0045 and P = 0.0454). Cut-off values were established between the MAFR + SEM and MAFNR - SEM values. On the basis of these cut-off levels, multidrug resistance (MDR) negativity showed a 72% predictive value for the response to chemotherapy, whereas MDR positivity was found to have an average predictive value of 69% for therapy failure. MDR activity was a prognostic factor for survival rate and the test was suitable for detecting patients at relapse. The calcein assay can be used as a quantitative, standardized, inexpensive screening test in a routine clinical laboratory setting. The assay detects both P-glycoprotein and multidrug resistance-associated protein activities, and identifies AML patients with unfavourable therapy responses.

KW - Acute myeloid leukaemia

KW - Calcein-AM

KW - P-glycoprotein

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=0035120672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035120672&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2001.02554.x

DO - 10.1046/j.1365-2141.2001.02554.x

M3 - Article

VL - 112

SP - 308

EP - 314

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -